- Home
- AES vs EXEL Comparison
AES vs EXEL Comparison
Compare AES & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AES
- EXEL
- Stock Information
- Founded
- AES 1981
- EXEL 1994
- Country
- AES United States
- EXEL United States
- Employees
- AES N/A
- EXEL N/A
- Industry
- AES Electric Utilities: Central
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AES Utilities
- EXEL Health Care
- Exchange
- AES Nasdaq
- EXEL Nasdaq
- Market Cap
- AES 10.3B
- EXEL 10.4B
- IPO Year
- AES 1991
- EXEL 2000
- Fundamental
- Price
- AES $14.56
- EXEL $38.70
- Analyst Decision
- AES Hold
- EXEL Buy
- Analyst Count
- AES 10
- EXEL 22
- Target Price
- AES $14.89
- EXEL $44.10
- AVG Volume (30 Days)
- AES 12.7M
- EXEL 2.9M
- Earning Date
- AES 11-04-2025
- EXEL 11-04-2025
- Dividend Yield
- AES 4.84%
- EXEL N/A
- EPS Growth
- AES 8.40
- EXEL 81.76
- EPS
- AES 1.28
- EXEL 2.08
- Revenue
- AES $12,032,000,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- AES $1.18
- EXEL $9.14
- Revenue Next Year
- AES $4.58
- EXEL $12.59
- P/E Ratio
- AES $11.27
- EXEL $18.65
- Revenue Growth
- AES N/A
- EXEL 10.73
- 52 Week Low
- AES $9.46
- EXEL $27.86
- 52 Week High
- AES $17.37
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- AES 56.82
- EXEL 50.57
- Support Level
- AES $13.98
- EXEL $33.76
- Resistance Level
- AES $14.79
- EXEL $40.53
- Average True Range (ATR)
- AES 0.38
- EXEL 1.30
- MACD
- AES -0.05
- EXEL -0.15
- Stochastic Oscillator
- AES 56.59
- EXEL 72.99
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.